Boston Scientific completes Bard EP takeover

Boston Scientific has announced the completion of its takeover of the electrophysiology business of Bard, a move that will strengthen the company's growth prospects in the coming years.

The company has purchased the Bard EP business in order to provide a broader portfolio of electrophysiology tools, including solutions for cardiac catheter ablations, advanced therapeutic and diagnostic catheters, electrophysiology recording systems and intracardiac access devices.

Its acquisition will also extend the firm's reach in strategic global markets, thus helping to accelerate the launches of key products such as the recently approved IntellaTip MiFi XP ablation catheter and next-generation Rhythmia Mapping System.

Pete Sommerness, general manager for electrophysiology at Boston Scientific, said: "We believe that the complementary capabilities that this transaction brings … will enable us to offer more complete solutions to help electrophysiologists diagnose and treat patients with cardiac arrhythmias."

This comes after the company reported a year-on-year operational sales increase of four percent for the third quarter of 2013.